Net Revenue Expected to Grow 34%+ in 2025 to $4.2 Million, up From Previous Guidance of $4.0 Million
Product Expansion and Growth in Subscription-Based Recurring Revenue Continues to Drive Positive Cash Flow
LAS VEGAS, NEVADA / ACCESS Newswire / April 17, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported preliminary results for the first quarter ended March 31, 2025.
Net revenue is expected to exceed a record $925,000, up more than 19% sequentially and up more than 34% versus the same year-ago quarter.
Direct-to-consumer subscription-based customers increased 83% and Amazon "Subscribe & Save" customers increased 81% as compared to the year ago quarter. In addition to the benefits of generating recurring revenue, subscriptions enhance customer communications, improve customer retention and extend customer lifetime value.
"After generating record-breaking revenue and our first-ever positive adjusted EBITDA in 2024, this momentum continued into the first quarter," stated Healthy Extracts president, Duke Pitts. "These results once again demonstrate our strengthening performance across our direct-to-consumer and retail channels for both our traditional and new product offerings.
"We also maintained our top three Amazon ranking in our category, with this success due to our well-tuned marketing strategies and perhaps more so our unique formulations that our customers find so valuable for supporting their heart and brain health.
"As the result of years of research and development, we plan to soon launch several new product formulations representing new product categories. We will cross-promote these products across our sales channels like never before and thereby position us to drive substantial increases in revenues and profitability over the coming quarters and beyond.
"We then plan to drive future growth by reinvesting our profits into new product development and channel expansion, including the development and launch of new oral delivery systems based on exclusive IP."
Healthy Extracts is planning to soon launch several new products:
-
Revolutionary heart health formulation targeting an unmet need of more than 40 million statin users in the U.S.
-
MYNUS sugar blocker specially formulated to reduce up to 42% of the sugar impact from meals. The MYNUS on-the-go gel-packs will be made available under the company's exclusive U.S. and Canadian licensing and manufacturing agreement with Gelteq.
-
Hydrate EZ: on-the-go gel pack specially formulated to provide hydration, focus, recovery, and sleep benefits without need for mixing.
Healthy Extracts' top brand ambassador and renowned fitness expert, Whitney Johns, is also preparing to launch WHITNEY JOHNS™ NUTRITION on-the-go gel packs for gut health in the second quarter of 2025.
In the second half of 2025, the company plans to launch COLLAGEN (anti-aging) in an on-the-go gel pack. These products will be based on Healthy Extracts' exclusive oral delivery system and proprietary formulations.
"We believe our commitment to customer retention, product innovation, and strategic engagement continues to differentiate our company and brands from the competition," added Pitts. "Given the strong leverage we have created in our business model, we see each of these new products generating on their own millions in additional annual revenues with high gross margins.
"We also believe that our solid cash flow and a highly favorable capitalization structure strengthens our ability to pursue certain opportunistic M&A opportunities, particularly those which would provide additional exclusive IP that differentiates us from our industry peers. Altogether, we remain well positioned for another year of record growth in revenues, cash flow and shareholder value."
2025 Outlook
Based upon the strong revenue performance in the first quarter of 2025 and better visibility into the remainder of the year, the company has increased its outlook for total net revenue in 2025 to more than $4.2 million, representing growth of more than 34% over 2024. This compares to the company's previous guidance for 2025 of more than $4.0 million.
New product launches across new categories and formats that are scheduled for throughout the year are expected to drive this growth with greater profitability (excluding non-cash-based expenses).
The new products are expected to benefit from the broad market channels the company has strategically developed and invested in over the last several years. The company plans to drive future growth by reinvesting its profits into new product development and channel expansion.
The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its quarterly results in May.
About Healthy Extracts "Live Life Young Again"
Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals.
The company's subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids.
UBN's KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2025, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food & Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™
Use of Non-GAAP Measures
This press release contains financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which are EBITDA and adjusted EBITDA. EBITDA is defined for the purposes of this press release as net income before Income tax expense, Interest expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding the gain or loss related to stock-based option/warrant expense, change in fair value of derivative, and offering costs.
Healthy Extracts' management believes that EBITDA and adjusted EBITDA are useful supplemental measures of our operating performance and provide our investors meaningful measures of overall corporate performance. EBITDA is also presented because management believes that it is frequently used by investment analysts, investors, and other interested parties as a measure of financial performance. Adjusted EBITDA is also presented because management believes that it provides our investors additional measures of our core business. However, non-GAAP measures do not have a standardized meaning prescribed by GAAP, and investors are cautioned that non-GAAP measures, such as EBITDA and adjusted EBITDA, should not be construed as an alternative to net income or loss or other income statement data (which are determined in accordance with GAAP) as an indicator of our performance or as a measure of liquidity and cash flows. Management's method of calculating EBITDA and adjusted EBITDA may differ materially from the method used by other companies and, accordingly, may not be comparable to similarly titled measures used by other companies. The Company provided a reconciliation of EBITDA and adjusted EBITDA to net income, the most comparable GAAP measure, in its year-ended December 31, 2024 press release issued on April 1, 2025.
Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor Contact
CMA Investor Relations
Tel (949) 432-7554
Email contact
SOURCE: HEALTHY EXTRACTS INC.
View the original press release on ACCESS Newswire
